AMARILLO, TX--(Marketwire - April 14, 2008) - Amarillo Biosciences, Inc. (OTCBB: AMAR), a specialty pharmaceutical company focused on low-dose orally administered interferon as a treatment for a variety of conditions, today announced that Peter Mueller, Ph.D. has been appointed Chief Operating Officer and Director of Research. Dr. Mueller will be responsible for research and development, business development, licensing, global commercial development, production and administration at the company. He will be actively involved in the development of strategic alliances and business opportunities with other companies and organizations.
